2023澳洲5历史开奖记录,官网开奖结果体彩|幸运澳洲5查询号码APP官方|澳洲五开奖官网直播
NurOwn, Brainstorm Cell Therapeutics’ experimental stem cell therapy for ALS, did not win the backing of an independent panel of FDA advisors. Many advisory committee members said they want to see more data from another clinical trial, the same guidance the FDA has given the biotech for nearly three years.